Mitochondrial Dysfunction Brief: References

Research Advisory Committee on Gulf War Veterans’ Illnesses (RAC-GWVI)

Mitochondrial Dysfunction Brief: References

Mitochondrial Dysfunction Brief: References

1.Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cellular and Molecular Biology. 1997;43:741-9.

2.Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors. 1999;9:253-60.

3.Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. Journal of the Neurological Sciences. 1998;156:41-6.

4.Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. European Neurology. 1997;37:212-8.

5.Darley-Usmar VM, Kennaway NG, Buist NR, Capaldi RA. Deficiency in ubiquinone cytochrome c reductase in a patient with mitochondrial myopathy and lactic acidosis. Proc Natl Acad Sci U S A. 1983;80:5103-6.

6.Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001;57:515-8.

7.England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin [letter]. Australian and New Zealand Journal of Medicine. 1995;25:374-5.

8.Fosslien E. Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001;31:25-67.

9.Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-82.

10.Takusa Y, Yamaguchi S. [Myopathies with miscellaneous disorders related to mitochondrial fatty acid oxidation: defective synthesis of ketone body, long-chain fatty acid transport defect, and muscular coenzyme Q10 deficiency]. Ryoikibetsu Shokogun Shirizu. 2001:90-4.

11.Tedeschi D, Lombardi V, Mancuso M, et al. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: new diagnostic approaches for new rationale therapeutics. Neurol Sci. 2000;21:S979-80.

12.Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998;280:981-988.

13.Bowman PD, Schuschereba ST, Johnson TW, et al. Myopathic changes in diaphragm of rats fed pyridostigmine bromide subchronically. Fundam Appl Toxicol. 1989;13:110-7.

14.Glass-Marmor L, Chen-Zion M, Beitner R. Effects of carbamylcholine and pyridostigmine on cytoskeleton-bound and cytosolic phosphofructokinase and ATP levels in different rat tissues. Gen Pharmacol. 1996;27:1241-6.

15.Glass-Marmor L, Beitner R. Effects of carbamylcholine and pyridostigmine on mitochondrial-bound hexokinase in skeletal muscle and heart. Biochem Mol Med. 1996;57:67-70.

16.Hudson CS, Foster RE, Kahng MW. Neuromuscular toxicity of pyridostigmine bromide in the diaphragm, extensor digitorum longus, and soleus muscles of the rat. Fundam Appl Toxicol. 1985;5:S260-9.

17.Kato T, Sugiyama S, Hanaki Y, et al. Role of acetylcholine in pyridostigmine-induced myocardial injury: possible involvement of parasympathetic nervous system in the genesis of cardiomyopathy. Arch Toxicol. 1989;63:137-43.

18.Schuschereba ST, Bowman PD, Vargas JA, Johnson TW, Woo FJ, McKinney L. Myopathic alterations in extraocular muscle of rats subchronically fed pyridostigmine bromide. Toxicol Pathol. 1990;18:387-95.

19.Kawabuchi M. Neostigmine myopathy is a calcium ion-mediated myopathy initially affecting the motor end-plate. J Neuropathol Exp Neurol. 1982;41:298-314.

20.Babu SR, Buckenmeyer P, Knowlton RG, Somani SM. Effect of physostigmine on plasma lactate and pyruvate in untrained/trained rats. Pharmacol Biochem Behav. 1992;42:67-73.

21.De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. British Journal of Clinical Pharmacology. 1996;42:333-7.

22.King BF, Somani SM. Distribution of physostigmine and metabolites in brain subcellular fractions of the rat. Life Sci. 1987;41:2007-15.

23.Li L, Gunaseker PG, Borowitz JL, Isom GE. Pyridostigmine-induced acute and delayed neuronal apoptosis [abstract]. Soc Toxicol Abstract. 1999.

24.Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis. Neurotoxicology. 2000;21:541-52.

25.Isom GE. Pyridostigmine-induced neurodegeneration: role of neuronal apoptosis. In: The Research Working Group of the Persian Gulf Veterans Coordinating Board, ed. Annual Report to Congress: Federally Sponsored Research on Gulf War Veterans' Illnesses for 1998. Appendices; 1999:100.

26.Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors. Toxicol Appl Pharmacol. 2001;177:17-25.

27.Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem. 1997;272:21388-95.

28.Haley RW, Marshall WW, McDonald GG, Daugherty MA, Petty F, Fleckenstein JL. Brain abnormalities in Gulf War syndrome: Evaluation with 1H MR spectroscopy. Radiology. 2000;215:807-817.

29.Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol. 2000;68:55-64.

30.Powell MF, Newman MJ. Chapter 8. Adjuvant properties of aluminum and calcium compounds. Vaccine Design. The Subunit and Adjuvant Approach. New York: Plenum Press; 1995.

31.Melinda Plaisier, FDA Associate Commissioner of Legislation, Letter to Congressmand Jack Metcalf, 20 March 2000. Cited in: [Committee on Government Reform Hearings for the United States House of Representatives, 2000 #1320]. 2000.

32.Ivins B, Fellows P, Pitt L, et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 1995;13:1779-84.

33.Ivins B, et al. Adjuvant efficacy in experimental anthrax vaccines: Protection studies in guinea pigs. Abstracts of the 91st General Meeting of the American Society for Microbiology. 1991:121.

34.Matsumoto G. The Pentagon's toxic secret. Vanity Fair; 1999:83-96.

35.Tomich N. Anthrax vaccine program scrutiny intensifies. U.S. Medicine. 2000;36:1,32,33,36.

36.Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol. 2000;156:2057-65.

37.Gajkowska B, Smialek M, Ostrowski RP, Piotrowski P. The experimental squalene encephaloneuropathy in the rat. Exp Toxicol Pathol. 1999;51:75-80.

38.Lorentzen JC. Identification of arthritogenic adjuvants of self and foreign origin. Scand J Immunol. 1999;49:45-50.

39.Sverdrup B, Klareskog L, Kleinau S. Common commercial cosmetic products induce arthritis in the DA rat. Environ Health Perspect. 1998;106:27-32.

40.Dijkstra J, Swartz GM, Jr., Raney JJ, et al. Interaction of anti-cholesterol antibodies with human lipoproteins. J Immunol. 1996;157:2006-13.

41.Ordovas JM. Anticholesterol antibodies and plaque formation. Nutr Rev. 1996;54:124-7.

42.Alving CR, Swartz GM, Jr., Wassef NM, et al. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab Clin Med. 1996;127:40-9.

43.Alving CR, Wassef NM, Potter M. Antibodies to cholesterol: biological implications of antibodies to lipids. Curr Top Microbiol Immunol. 1996;210:181-6.

44.Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 1993;36:1566-74.

45.Alving CR, Swartz GM, Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol. 1991;10:441-53.

46.Alving CR. Antibodies to liposomes, phospholipids, and cholesterol: implications for autoimmunity, atherosclerosis, and aging. Prog Clin Biol Res. 1990;343:41-51.

47.Swartz GM, Jr., Gentry MK, Amende LM, Blanchette-Mackie EJ, Alving CR. Antibodies to cholesterol. Proc Natl Acad Sci U S A. 1988;85:1902-6.

48.Folkers K, Nilsson JL. [Coenzyme Q regarded as a vitamin]. Nord Med. 1970;83:489-93.

49.Estornell E, Tormo JR, Marin P, Renau-Piqueras J, Timoneda J, Barber T. Effects of vitamin A deficiency on mitochondrial function in rat liver and heart. Br J Nutr. 2000;84:927-34.

50.Anderson SS, Lyle IG, Paterson R. Electron transfer across membranes using vitamin K1 and coenzyme Q10 as carrier molecules. Nature. 1976;259:147-8.

51.Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997;48:1238-43.

52.DiMauro S, Bonilla E, Davidson M, Hirano M, Schon EA. Mitochondria in neuromuscular disorders. Biochimica et Biophysica Acta. 1998;1366:199-210.

53.Suzuki Y, Kadowaki H, Atsumi Y, et al. A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocrine Journal. 1995;42:141-5.

54.Hansen IL, Iwamoto Y, Kishi T, Folkers K, Thompson LE. Bioenergetics in clinical medicine. IX. Gingival and leucocytic deficiencies of coenzyme Q10 in patients with periodontal disease. Res Commun Chem Pathol Pharmacol. 1976;14:729-38.

55.Wilkinson EG, Arnold RM, Folkers K, Hansen I, Kishi H. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol. 1975;12:111-23.

56.Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta. 1995;1271:281-6.

57.Kuz'menko IV, Donchenko GV, Kovalenko VN, Gololobov AD, Tarasova NV. [Efficiency of ubiquinone and p-oxybenzoic acid in prevention of E-hypovitaminosis-induced development of muscular dystrophy]. Ukr Biokhim Zh. 1981;53:73-9.

58.Shimomura Y, Suzuki M, Sugiyama S, Hanaki Y, Ozawa T. Protective effect of coenzyme Q10 on exercise-induced muscular injury. Biochem Biophys Res Commun. 1991;176:349-55.

59.Muller DP, Lloyd JK, Wolff OH. Vitamin E and neurological function: abetalipoproteinaemia and other disorders of fat absorption. Ciba Found Symp. 1983;101:106-21.

60.Muller DPR, Lloyd JK, Bird A. Long-term management of abetalipoproteinemia. Possible role for vitamin E. Arch Dis Child. 1977;52:209-14.

61.Azizi E, Zaidman JL, Eschar J, Aszeinberg A. Abetalipoproteinemia treated with parenteral and oral vitamin A and E and with medium chain triglycerides. Acta Pediatr Scand. 1978; 67:797-801.

62.Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy. Can Med Assoc J. 1985;132:41-4.

63.Iannaccone ST, Sokol RJ. Vitamin E deficiency in neuropathy of abetalipoproteinemia. Neurology. 1986;36:1009.

64.Alleva R, Tomasetti M, Andera L, et al. Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett. 2001;503:46-50.

65.Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid Redox Signal. 2000;2:263-75.

66.Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann N Y Acad Sci. 1999;887:31-47.

67.Mosca L, Marcellini S, Perluigi M, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63:1305-14.

68.Buckenmeyer PJ, Babu SR, Knowlton RG, Somani SM. Effect of concurrent exercise and physostigmine on lactate and pyruvate in plasma, muscle, and brain tissue of rats. Pharmacol Biochem Behav. 1994;47:779-88.

69.Phillips P, et al. Title Not Yet on Current Contents. Annals of Internal Medicine. 2002;Oct 1, 2002:Pages to be secured.

70.Ackrell BA, Maguire JJ, Dallman PR, Kearney EB. Effect of iron deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria. J Biol Chem. 1984;259:10053-9.

71.Shingwekar AG, Mohanram M, Reddy V. Effect of zinc supplementation on plasma levels of vitamin A and retinol-binding protein in malnourished children. Clin Chim Acta. 1979;93:97-100.

72.Vadhanavikit S, Ganther HE. Decreased ubiquinone levels in tissues of rats deficient in selenium. Biochem Biophys Res Commun. 1993;190:921-6.

73.Pedersen HS, Mortensen SA, Rohde M, et al. High serum coenzyme Q10, positively correlated with age, selenium and cholesterol, in Inuit of Greenland. A pilot study. Biofactors. 1999;9:319-23.

74.Pelton R, La Valle JB, Hawkins EB, Krinsky DL. Drug-Induced Nutrient Depletion Handbook 1999-2000. Hudson, Ohio: Lexi-Comp, Inc; 1999:485.

75.Pfizer reports 38% increase. San Diego Union Tribune, January 24. San Diego; 2002.

76.Sinzinger H. Does vitamin E beneficially affect muscle pains during HMG-Co-A-reductase inhibitors without CK-elevation. Atherosclerosis. 2000;149:225.

77.Sinzinger H, Chehne F, Lupattelli G. Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without Enzyme Elevation or Myopathy. Drug Saf. 2002;25:877-83.

78.Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK -elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis. 1999;143:459-460.

79.Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767-9.

80.Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538-46.

81.Bruckert E, Simonetta C, Giral P. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. J Clin Epidemiol. 1999;52:589-94.

82.Gaist D, Jeppesen M, Andersen LA, Garcia Rodriguez J, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: A case-control study. Neurology. 2002;58:1333-1337.

83.Blasiak J, Walter Z. Protective action of cholesterol against changes in membrane fluidity induced by malathion. Acta Biochimica Polonica. 1992;39:49-52.

84.Nevin DN, Zambon A, Furlong CE, et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol. 1996;16:1243-9.

85.Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol. 1975;12:533-40.

86.Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Res Commun Chem Pathol Pharmacol. 1977;17:157-64.

87.Reyes AJ, Leary WP, Lockett CJ, Alcocer L. Diuretics and zinc. S Afr Med J. 1982;62:373-5.

88.Cohanim M, Yendt ER. The effects of thiazides on serum and urinary zinc in patients with renal calculi. Johns Hopkins Med J. 1975;136:137-41.

89.Mountokalakis T, Dourakis S, Karatzas N, Maravelias C, Koutselinis A. Zinc deficiency in mild hypertensive patients treated with diuretics. J Hypertens Suppl. 1984;2:S571-2.

90.Lockett CJ, Reyes AJ, Leary WP, Alcocer L, Olhaberry JV. Zinc, angiotensin I-converting enzyme and hypertension. S Afr Med J. 1983;64:1022-4.

91.Bunning P, Riordan JF. The functional role of zinc in angiotensin converting enzyme: implications for the enzyme mechanism. J Inorg Biochem. 1985;24:183-98.

92.Reeves PG, O'Dell BL. An experimental study of the effect of zinc on the activity of angiotensin converting enzyme in serum. Clin Chem. 1985;31:581-4.

93.Reeves PG, O'Dell BL. Effects of dietary zinc deprivation on the activity of angiotensin-converting enzyme in serum of rats and guinea pigs. J Nutr. 1986;116:128-34.

94.White CL, Pschorr J, Jacob IC, von Lutterotti N, Dahlheim H. The effect of zinc in vivo and in vitro on the activities of angiotensin converting enzyme and kininase-I in the plasma of rats. Biochem Pharmacol. 1986;35:2489-93.

95.Schullek JR, Wilson IB. The binding of zinc to angiotensin-converting enzyme. Arch Biochem Biophys. 1988;265:346-50.

96.Dahlheim H, White CL, Rothemund J, von Lutterotti N, Jacob IC, Rosenthal J. Effect of zinc depletion on angiotensin I-converting enzyme in arterial walls and plasma of the rat. Miner Electrolyte Metab. 1989;15:125-9.

97.Kagan BL, Leskin G, Haas B, Wilkins J, et al. Elevated lipid levels in Vietnam veterans with chronic posttraumatic stress disorder. Biological Psychiatry. 1999;45:374-377.

98.Peter H, Tabrizian S, Hand I. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo. International Journal of Psychiatry in Medicine. 2000;30:27-39.

99.Kuczmierczyk AR, Barbee JG, Bologna NA, Townsend MH. Serum cholesterol levels in patients with generalized anxiety disorder (GAD) and with GAD and comorbid major depression. Canadian Journal of Psychiatry. 1996;41:465-8.

100.Bajwa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM. High cholesterol levels in patients with panic disorder. American Journal of Psychiatry. 1992;149:376-378.

101.Bajwa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM. High cholesterol levels in patients with panic disorder. Am J Psychiatry. 1992;149:376-8.

102.Hayward C, Taylor C, Roth W, King R, Agras W. Plasma lipid levels in patients with panic disorder or agoraphobia. Am J Psychiatry. 1989;146:917-9.

103.Patterson S, Gottdiener J, Hecht G, Vargot S, Krantz D. Effects of acute mental stress on serum lipids: mediating effects of plasma volume. Psychosomatic Med. 1993;55:525-32.

104.Peterson J, Keith R, Wilcox A. Hourly changes in serum cholesterol concentration: Effects of the anticipation of stress. Circulation. 1962;25:798-803.

105.Thomas C, Murphy E. Further studies on cholesterol levels in the Johns Hopkins medical students: the effect of stress at examinations. J Chron Dis. 1958;8:661-8.

106.Wertlake P, Wilcox A, Haley M, Peterson J. Relationship of mental and emotional stress to serum cholesterol levels. Proc Soc Exper Biol & Med. 1958;97:163.

107.Muldoon M, Herbert T, Patterson S, Kameneva M, Raible R, Manuck S. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Intern Med. 1995;155:615-20.

108.Muldoon M, Bachen E, Manuck S, Waldstein S, Bricker P, Bennett J. Acute cholesterol responses to mental stress and change in posture. Arch Intern Med. 1992;152:775-80.

109.McCabe W, Hammarsten J, Scjhottstaedt W, Adsett C, Yamamoto J, Wold S. Elevations of serum cholesterol in man in association with life stress and independent of diet and exercise. Abstract, J. Lab & Clin Med. 1959;54:922.

110.Dreyfuss F, Czaczkes J. Blood cholesterol and uric acid of healthy medical students under the stress of an examination. Ann Intern Med. 1959;103:708-11.

111.Muldoon M, Herbert T, Patterson S, Kameneva M, Raible R, Manuck S. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Intern Med. 1995;155:615-20.

112.Patterson S, Gottdiener J, Hecht G, Vargot S, Krantz D. Effects of acute mental stress on serum lipids: mediating effects of plasma volume. Psychosomatic Med. 1993;55:525-32.

113.Hata S, Kunida H, Oyama Y. [Antihypertensive effects of coenzyme Q10 in essential hypertension--in relation to the renin-aldosterone system]. Horumon To Rinsho. 1977;25:1019-23.

114.Hamdy BH, Elnokaly F, Gaafar S, Elnaggar B, Hussein L. Effectiveness of periodic oral vitamin A dosage on hypovitaminosis in Egypt. Int J Vitam Nutr Res. 1982;52:235-40.

115.Marinho HA, Shrimpton R, Giugliano R, Burini RC. Influence of enteral parasites on the blood vitamin A levels in preschool children orally supplemented with retinol and/or zinc. Eur J Clin Nutr. 1991;45:539-44.

116.Morris MC. Archives of Neurology. 2002;59:1125-32.

117.Vitamin E slows cognitive decline in the elderly. Internal Medicine World Report. 2002:4.

118.Sato Y, Honda Y, Asoh T, Kikuyama M, Oizumi K. Hypovitaminosis D and decreased bone mineral density in amyotrophic lateral sclerosis. Eur Neurol. 1997;37:225-9.

119.Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med. 2000;160:1199-203.

120.Gennari A, Viviani B, Galli CL, Marinovich M, Pieters R, Corsini E. Organotins induce apoptosis by disturbance of [Ca(2+)](i) and mitochondrial activity, causing oxidative stress and activation of caspases in rat thymocytes. Toxicol Appl Pharmacol. 2000;169:185-90.

121.Ravikumar A, Arun P, Devi KV, Augustine J, Kurup PA. Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol. 2000;38:438-46.

1